Alicia Roldán

518 total citations
27 papers, 272 citations indexed

About

Alicia Roldán is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Genetics. According to data from OpenAlex, Alicia Roldán has authored 27 papers receiving a total of 272 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Alicia Roldán's work include Growth Hormone and Insulin-like Growth Factors (6 papers), Metabolism, Diabetes, and Cancer (4 papers) and Analytical Chemistry and Chromatography (3 papers). Alicia Roldán is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (6 papers), Metabolism, Diabetes, and Cancer (4 papers) and Analytical Chemistry and Chromatography (3 papers). Alicia Roldán collaborates with scholars based in Argentina, Spain and United Kingdom. Alicia Roldán's co-authors include Roxana Schillaci, Mariana Brocardo, Elsie M. Eugui, David Cunningham, S Milan, Eduardo H. Charreau, David MacVicar, Ralph McCready, Janine Mansi and Cristina M. Rondinone and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Diabetes.

In The Last Decade

Alicia Roldán

25 papers receiving 256 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alicia Roldán Argentina 10 84 76 58 50 43 27 272
Margita Zakarija United States 10 376 4.5× 94 1.2× 114 2.0× 38 0.8× 37 0.9× 13 464
L. Fedeli Italy 10 79 0.9× 84 1.1× 27 0.5× 41 0.8× 24 0.6× 25 331
Luca Mariani Italy 11 48 0.6× 155 2.0× 104 1.8× 49 1.0× 44 1.0× 28 396
Jane Redford United Kingdom 5 45 0.5× 70 0.9× 76 1.3× 10 0.2× 62 1.4× 5 332
Maria Kalina Poland 9 113 1.3× 174 2.3× 90 1.6× 15 0.3× 39 0.9× 26 370
Gili Hart Israel 13 153 1.8× 130 1.7× 80 1.4× 11 0.2× 99 2.3× 27 407
Patricia L. Monteleone United States 13 31 0.4× 147 1.9× 96 1.7× 25 0.5× 13 0.3× 31 346
Geneviève Beaurain France 8 52 0.6× 93 1.2× 64 1.1× 10 0.2× 94 2.2× 9 349
J‐E. Damber Sweden 10 120 1.4× 106 1.4× 28 0.5× 15 0.3× 31 0.7× 16 364
YACHIYO NOHARA Japan 5 298 3.5× 64 0.8× 68 1.2× 16 0.3× 21 0.5× 9 339

Countries citing papers authored by Alicia Roldán

Since Specialization
Citations

This map shows the geographic impact of Alicia Roldán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alicia Roldán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alicia Roldán more than expected).

Fields of papers citing papers by Alicia Roldán

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alicia Roldán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alicia Roldán. The network helps show where Alicia Roldán may publish in the future.

Co-authorship network of co-authors of Alicia Roldán

This figure shows the co-authorship network connecting the top 25 collaborators of Alicia Roldán. A scholar is included among the top collaborators of Alicia Roldán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alicia Roldán. Alicia Roldán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gros, Luis, Alicia Roldán, Nerea Domínguez‐Pinilla, et al.. (2022). Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study. Journal of Oncology Pharmacy Practice. 29(4). 794–801. 13 indexed citations
3.
Roldán, Alicia, et al.. (2014). Effect of stage of the estrous cycle at the time of initial exposure to rams on the ovarian activity of Pelibuey ewes. Czech Journal of Animal Science. 59(11). 504–510. 9 indexed citations
4.
Segretin, María Eugenia, et al.. (2003). Insulin-Like Growth Factor-1 Receptor Regulation in Activated Human T Lymphocytes. Hormone Research in Paediatrics. 59(6). 276–280. 17 indexed citations
5.
Schillaci, Roxana, et al.. (1998). Downregulation of Insulin-like Growth Factor-1 Receptor (IGF-1R) Expression in Human T Lymphocyte Activation. Cellular Immunology. 183(2). 157–161. 24 indexed citations
6.
Schillaci, Roxana, C. Ribaudo, Cristina M. Rondinone, & Alicia Roldán. (1994). Role of insulin‐like growth factor‐1 on the kinetics of human lymphocytes stimulation in serum‐free culture medium. Immunology and Cell Biology. 72(4). 300–305. 13 indexed citations
7.
Schillaci, Roxana, Elsie M. Eugui, & Alicia Roldán. (1994). Insulin Effect on Interleukin 1 (IL-1) and Interleukin 6 (IL-6) Production by Lipopolysaccharide-Stimulated Human Monocytes. Hormone and Metabolic Research. 26(2). 113–115. 4 indexed citations
8.
Hill, M., David Cunningham, David MacVicar, et al.. (1993). Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.. Journal of Clinical Oncology. 11(11). 2273–2278. 53 indexed citations
9.
Rondinone, Cristina M., Roxana Schillaci, & Alicia Roldán. (1992). Anti‐Inflammatory activity of 11β‐hydroxypregna‐1,4‐diene‐3,20‐dione. Drug Development Research. 26(1). 61–65. 3 indexed citations
10.
Roldán, Alicia, et al.. (1990). Effect of 11 beta OH pregna-1,4-diene-3,20-dione (delta HOP) on thymocyte plasma membranes.. PubMed. 40(3). 357–64. 1 indexed citations
11.
Schillaci, Roxana, et al.. (1989). Appearance and persistence of 11 beta-hydroxypregna-1,4-diene-3,20-dione (delta HOP) effect "in vivo".. PubMed. 39(2). 181–8. 2 indexed citations
12.
Roldán, Alicia, et al.. (1989). Insulin-like growth factor-1 increases the mitogenic response of human peripheral blood lymphocytes to phytohemagglutinin. Immunology Letters. 20(1). 5–8. 32 indexed citations
13.
González, Mario D., et al.. (1986). Mechanism of the inhibitory effect of 11 beta-hydroxypregna-1, 4-diene-3, 20-dione (delta HOP) at high concentrations in RNA synthesis.. PubMed. 36(3). 303–12. 1 indexed citations
14.
Roldán, Alicia, et al.. (1984). Modulation of Glucocorticoid Effect in Thymus of Adrenalectomized-Diabetic Rat. Hormone and Metabolic Research. 16(1). 17–21. 9 indexed citations
15.
González, Mario D., et al.. (1983). Dissociation of glucocorticoid effects of C-21 steroids at high concentrations in thymocytes. Cellular and Molecular Life Sciences. 39(6). 617–618. 4 indexed citations
16.
Roldán, Alicia, et al.. (1981). Inhibition of thymocyte RNA synthesis by natural adrenal steroids and their 1,4-diene analogs. Structure-activity correlations using 13C-n.m.r. spectroscopy. Journal of Steroid Biochemistry. 15. 467–472. 11 indexed citations
17.
Burton, Gerardo, et al.. (1981). Structure-activity relationship in certain glucocorticoids and mineralocorticoids.. PubMed. 74. 477–94. 7 indexed citations
18.
Roldán, Alicia, et al.. (1980). Effect of streptozotocin-diabetes on thymus of normal and adrenalectomized rats.. PubMed. 30(3). 205–10. 3 indexed citations
19.
Roldán, Alicia, John Stevens, & Vincent P. Hollander. (1976). Difference in the Number of Insulin Binding Sites between Cortisol-Sensitive and Cortisol-Resistant Lymphoma P1798 Cells. Experimental Biology and Medicine. 151(4). 711–715. 2 indexed citations
20.
Houssay, B. A., et al.. (1967). Fatty Metabolism and Ketogenesis after Liver Denervation or Bilateral Thoracolumbar Sympathectomy in Pancreatectomized Dogs. Diabetes. 16(4). 259–263. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margita Zakarija Breakdown of academic impact, for papers by L. Fedeli Breakdown of academic impact, for papers by Luca Mariani Breakdown of academic impact, for papers by Jane Redford Breakdown of academic impact, for papers by Maria Kalina Breakdown of academic impact, for papers by Gili Hart Breakdown of academic impact, for papers by Patricia L. Monteleone Breakdown of academic impact, for papers by Geneviève Beaurain Breakdown of academic impact, for papers by J‐E. Damber Breakdown of academic impact, for papers by YACHIYO NOHARA
Rankless by CCL
2026